Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trial
ESMO Open · 2026-04-01
Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02
Annals of Oncology · 2025-11-20 · 4 citations
Corrigendum to “Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3”
Annals of Oncology · 2025-10-15 · 1 citations
496P Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials
Annals of Oncology · 2025-09-01
MammaPrint predicts chemotherapy benefit in HR+HER2- early breast cancer: FLEX Registry real-world data
JNCI Cancer Spectrum · 2025-08-02 · 7 citations
Abstract PS2-05: PRESERVE 2: A randomized, phase 3, double-blind trial of trilaciclib or placebo in patients (pts) receiving first-line gemcitabine/carboplatin (GCb) for locally advanced or metastatic triple-negative breast cancer (mTNBC)
Clinical Cancer Research · 2025-06-13 · 2 citations
Abstract LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC
Clinical Cancer Research · 2025-06-13 · 9 citations
Abstract P4-11-04: Correlative analysis of Breast Cancer Index with Body Mass Index for prediction of extended endocrine therapy benefit in the BCI Registry study
Clinical Cancer Research · 2025-06-13
Abstract P1-11-24: Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine - Biology is Still King
Clinical Cancer Research · 2025-06-13
Abstract P1-11-16: Impact of ribociclib dose reduction on efficacy in patients with hormone receptor– "positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC) in NATALEE”
Clinical Cancer Research · 2025-06-13 · 3 citations
Abstract GS1-01: Imlunestrant, an Oral Selective Estrogen Receptor Degrader (SERD), as Monotherapy & Combined with Abemaciclib, for Patients with ER+, HER2- Advanced Breast Cancer (ABC), Pretreated with Endocrine Therapy (ET): Results of the Phase 3 EMBER-3 trial
Clinical Cancer Research · 2025-06-13 · 2 citations
Abstract P2-10-20: ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd)
Clinical Cancer Research · 2025-06-13
Abstract PS2-08: Association of MammaPrint® with gene expression pathways predictive of resistance to cyclin-dependent kinase inhibition
Clinical Cancer Research · 2025-06-13
Abstract P3-11-20: 2018 and 2024 surveys of clinical investigator (CI) use of postoperative systemic therapy after prior neoadjuvant treatment of HER2-positive breast cancer (HER2+BC)
Clinical Cancer Research · 2025-06-13
Abstract P2-08-12: Prediction of Chemotherapy Benefit by MammaPrint® in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Clinical Cancer Research · 2025-06-13 · 1 citations
Abstract PS4-04: MammaPrint® and BluePrint® predict pathological response to neoadjuvant chemotherapy in patients with HR+HER2- early-stage breast cancer enrolled in FLEX
Clinical Cancer Research · 2025-06-13 · 1 citations
Abstract PS7-03: A first-in-human phase 1a/b trial of LOXO-783, a potent, highly mutant-selective, brain-penetrant, allosteric PI3Kα H1047R inhibitor in PIK3CA H1047R-mutant advanced breast cancer and other solid tumors: Results from the PIKASSO-01 study
Clinical Cancer Research · 2025-06-13 · 2 citations
Abstract P4-03-25: Actionable gene alterations affecting the PI3K/AKT and MAPK signaling pathways in breast cancer
Clinical Cancer Research · 2025-06-13
Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis
ESMO Open · 2025-06-01 · 3 citations
The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study
ESMO Open · 2025-06-01 · 4 citations